{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:11:49Z","timestamp":1789989109729,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T00:00:00Z","timestamp":1331683200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00259-012-2083-2","type":"journal-article","created":{"date-parts":[[2012,3,13]],"date-time":"2012-03-13T16:13:04Z","timestamp":1331655184000},"page":"936-943","source":"Crossref","is-referenced-by-count":100,"title":["Clinical impact of 18F-choline PET\/CT in patients with recurrent prostate cancer"],"prefix":"10.1007","volume":"39","author":[{"given":"Jan D.","family":"Soyka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Muster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhardt","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Miralbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Jorcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Zaugg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Helge","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Veit-Haibach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Strobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklaus G.","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela B.","family":"Husarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Hany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,14]]},"reference":[{"key":"2083_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390. doi: 10.3322\/caac.20107 .","journal-title":"CA Cancer J Clin"},{"key":"2083_CR2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/jnci\/88.3-4.166","volume":"88","author":"GL Lu-Yao","year":"1996","unstructured":"Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 1996;88:166\u201373.","journal-title":"J Natl Cancer Inst"},{"key":"2083_CR3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.pcan.4500732","volume":"7","author":"SR Bott","year":"2004","unstructured":"Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis. 2004;7:211\u20136. doi: 10.1038\/sj.pcan.45007324500732 .","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2083_CR4","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0090-4295(93)90524-E","volume":"42","author":"FJ Fowler Jr","year":"1993","unstructured":"Fowler Jr FJ, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology. 1993;42:622\u20139.","journal-title":"Urology"},{"key":"2083_CR5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","volume":"294","author":"SJ Freedland","year":"2005","unstructured":"Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433\u20139. doi: 10.1001\/jama.294.4.433 .","journal-title":"JAMA"},{"key":"2083_CR6","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","volume":"59","author":"N Mottet","year":"2011","unstructured":"Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572\u201383. doi: 10.1016\/j.eururo.2011.01.025 .","journal-title":"Eur Urol"},{"key":"2083_CR7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","volume":"59","author":"A Heidenreich","year":"2011","unstructured":"Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61\u201371. doi: 10.1016\/j.eururo.2010.10.039 .","journal-title":"Eur Urol"},{"key":"2083_CR8","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, prostate cancer. 2010. Fort Washington: National Comprehensive Cancer Network"},{"key":"2083_CR9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1148\/radiol.2352040494","volume":"235","author":"DT Schmid","year":"2005","unstructured":"Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, et al. Fluorocholine PET\/CT in patients with prostate cancer: initial experience. Radiology. 2005;235:623\u20138. doi: 10.1148\/radiol.2352040494 .","journal-title":"Radiology"},{"key":"2083_CR10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eururo.2010.09.004","volume":"59","author":"M Picchio","year":"2011","unstructured":"Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of choline positron emission tomography\/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51\u201360. doi: 10.1016\/j.eururo.2010.09.004 .","journal-title":"Eur Urol"},{"key":"2083_CR11","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.eururo.2011.08.009","volume":"60","author":"S Fanti","year":"2011","unstructured":"Fanti S, Krause B, Weber W, Castellucci P, Grosu AL, de Jong IJ, et al. Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83. Eur Urol. 2011;60:e37\u20138; author reply e39\u201341. doi: 10.1016\/j.eururo.2011.08.009","journal-title":"Eur Urol"},{"key":"2083_CR12","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2967\/jnumed.108.061507","volume":"50","author":"P Castellucci","year":"2009","unstructured":"Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET\/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394\u2013400. doi: 10.2967\/jnumed.108.061507 .","journal-title":"J Nucl Med"},{"key":"2083_CR13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00259-007-0581-4","volume":"35","author":"BJ Krause","year":"2008","unstructured":"Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET\/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18\u201323. doi: 10.1007\/s00259-007-0581-4 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2083_CR14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00259-007-0552-9","volume":"35","author":"DB Husarik","year":"2008","unstructured":"Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET\/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:253\u201363. doi: 10.1007\/s00259-007-0552-9 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2083_CR15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11307-005-0023-2","volume":"8","author":"M Heinisch","year":"2006","unstructured":"Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, et al. Positron emission tomography\/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5\u00a0ng\/ml? Mol Imaging Biol. 2006;8:43\u20138. doi: 10.1007\/s11307-005-0023-2 .","journal-title":"Mol Imaging Biol"},{"key":"2083_CR16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00259-010-1604-0","volume":"38","author":"P Castellucci","year":"2011","unstructured":"Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, et al. Is there a role for 11C-choline PET\/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5\u00a0ng\/ml? Eur J Nucl Med Mol Imaging. 2011;38:55\u201363. doi: 10.1007\/s00259-010-1604-0 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2083_CR17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.radonc.2011.05.005","volume":"99","author":"M Souvatzoglou","year":"2011","unstructured":"Souvatzoglou M, Krause BJ, Purschel A, Thamm R, Schuster T, Buck AK, et al. Influence of (11)C-choline PET\/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99:193\u2013200. doi: 10.1016\/j.radonc.2011.05.005 .","journal-title":"Radiother Oncol"},{"key":"2083_CR18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1748-717X-6-44","volume":"6","author":"F Wurschmidt","year":"2011","unstructured":"Wurschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M. [18F]Fluoroethylcholine-PET\/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET\/CT-positive lymph nodes. Radiat Oncol. 2011;6:44. doi: 10.1186\/1748-717X-6-44 .","journal-title":"Radiat Oncol"},{"key":"2083_CR19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.eururo.2011.07.060","volume":"60","author":"P Rigatti","year":"2011","unstructured":"Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, et al. Pelvic\/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography\/computed tomography. Eur Urol. 2011;60:935\u201343. doi: 10.1016\/j.eururo.2011.07.060 .","journal-title":"Eur Urol"},{"key":"2083_CR20","first-page":"262","volume":"47","author":"SA Kwee","year":"2006","unstructured":"Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med. 2006;47:262\u20139.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-012-2083-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-012-2083-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-012-2083-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T16:05:20Z","timestamp":1558713920000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-012-2083-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,14]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["2083"],"URL":"https:\/\/doi.org\/10.1007\/s00259-012-2083-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,14]]}}}